Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia with TDP-43 pathology. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Transition Bio, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.…
Voyager Therapeutics Eyes Tau Antibody Data and Alzheimer’s Gene Therapy Dosing
Voyager Therapeutics (NASDAQ: VYGR) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 141 employees.
The shares were at 1.530 USD on 20 November 2026, down 63.7% over 52 weeks. Its 52-week range is 1.490 USD to 5.480 USD: the price is 72.1% below the high and 2.7% above the low.
Its market capitalisation is 95.21M USD.
Voyager Therapeutics reports return on equity of -61.1%, an operating margin of -436.2% and revenue down 70.0% year over year.
It holds more cash than debt, a net cash position of 76.30M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. The next earnings report is expected on 9 March 2027.